University of Colorado Anschutz Medical Campus ( Site 0151), Aurora
UCHealth Memorial Hospital Central ( Site 0125), Colorado Springs
Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207), Greeley
и уште 1

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06623422

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Rocky Mountain Cancer Centers, LLP, Pueblo

Се регрутираФаза 2/3

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07365319

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Lutheran Medical Center - Cancer Centers of Colorado, Wheat Ridge

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06472245

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #87, Littleton

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

University of Colorado Cancer Center ( Site 3268), Aurora

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07513376

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Kaiser Permanente-Franklin, Denver
Saint Mary's Hospital and Regional Medical Center, Grand Junction
Kaiser Permanente-Rock Creek, Lafayette
и уште 1

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Intermountain Health Cancer Center Lutheran Hospital, Golden

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07361497

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Local Institution - 0340, Lakewood

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Rocky Mountain Cancer Centers, Boulder

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT06765109

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Rocky Mountain Cancer Centers LLP, Aurora
Rocky Mountain Cancer Centers LLP, Boulder
Rocky Mountain Cancer Centers LLP, Centennial
и уште 11

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07144280

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132), Grand Junction

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06170788

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Rocky Mountain Cancer Centers, Lone Tree

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06667076

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Intermountain Health Cancer Center Lutheran Hospital, Golden
Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction
Intermountain Health St. Mary's Regional Hospital, Grand Junction
и уште 2

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06758401

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Rocky Mountain Cancer Centers,LLP, Aurora
Rocky Mountain Cancer Centers,LLP, Denver
Rocky Mountain Cancer Centers,LLP, Lone Tree

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07227298

Pan-tumor MRD Study

The Melanoma and Skin Cancer Institute, Englewood

Се регрутираНабљудувачка студија

Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT06605404

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Vail Health Hospital - Shaw Cancer Center, Edwards

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07140016

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0500, Grand Junction
Local Institution - 0472, Westminster

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT06561386

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

National Jewish Health Medical Center, Denver

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06875310

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Vail Health, Vail

Се регрутираФаза 2/3

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06712316

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Shaw Cancer Center, Edwards

Се регрутираФаза 2/3

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07100080

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

University of Colorado Cancer Center, Aurora

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06128551

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

University of Colorado Cancer Center, Aurora

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT05983432

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

SCRI at HCA HealthONE, Denver

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT07705334

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Aurora
Clinical Study Site, Denver
Clinical Study Site, Grand Junction
и уште 2

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT06767514

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

University of Colorado - Aurora Cancer Center, Aurora

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Local Institution - 007-872-H, Aurora
Local Institution - 007-872-D, Boulder
Local Institution - 007-872-L, Centennial
и уште 10

Се регрутираФаза 2/3

Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT04613596

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Rocky Mountain Cancer Centers, Lone Tree

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT04486833

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

University of Colorado, Aurora

Се регрутираНабљудувачка студија

Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT05059444

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora
Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's, Denver

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 10.9.2026 · NCT06914128

A Phase 1/1b Study of IAM1363 in HER2 Cancers

University of Colorado Cancer Center, Aurora

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT06253871

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

University of Colorado Health Hospital, Aurora
Sarah Cannon Research Institute at HealthOne, Denver

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06561685

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

USO - Rocky Mountain Cancer Centers, Lone Tree

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06119581

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

UC Health Oncology Research, Colorado Springs
Poudre Valley Health Care, Inc. d/b/a Poudre Valley Health System, Fort Collins

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06793215

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Grand Junction
Research Site, Wheat Ridge

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT07291037

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.